{"title":"Juno Therapeutics和Editas Medicine合作开发使用CRISPR/Cas9的下一代CAR-T疗法","authors":"Keshav Mahawar, Heather Cartwright","doi":"10.3833/pdr.v2015i6.2108","DOIUrl":null,"url":null,"abstract":"Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer. With the deal, Juno will leverage Editas’ CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) technology with the aim of expanding its pipeline into solid tumours.","PeriodicalId":19951,"journal":{"name":"Pharmadeals Review","volume":"79 1","pages":""},"PeriodicalIF":0.0000,"publicationDate":"2015-06-19","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9\",\"authors\":\"Keshav Mahawar, Heather Cartwright\",\"doi\":\"10.3833/pdr.v2015i6.2108\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer. With the deal, Juno will leverage Editas’ CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) technology with the aim of expanding its pipeline into solid tumours.\",\"PeriodicalId\":19951,\"journal\":{\"name\":\"Pharmadeals Review\",\"volume\":\"79 1\",\"pages\":\"\"},\"PeriodicalIF\":0.0000,\"publicationDate\":\"2015-06-19\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Pharmadeals Review\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.3833/pdr.v2015i6.2108\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Pharmadeals Review","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3833/pdr.v2015i6.2108","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
Juno Therapeutics and Editas Medicine Collaborate to Develop Next-Generation CAR-T Therapeutics Using CRISPR/Cas9
Signalling its intent to stay at the head of the cellular immunotherapy field, Juno Therapeutics has agreed to collaborate with genome editing specialist Editas Medicine to create next-generation chimeric antigen receptor (CAR-T) and high-affinity T cell receptor (TCR) therapies for the treatment of cancer. With the deal, Juno will leverage Editas’ CRISPR (clustered, regularly interspaced short palindromic repeats)/Cas9 (CRISPR-associated protein 9) technology with the aim of expanding its pipeline into solid tumours.
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
